Market Research Report
Depression Drugs - Global Market Outlook (2019 -2027)
|Published by||Stratistics Market Research Consulting||Product code||956154|
|Published||Content info||211 Pages
Delivery time: 2-3 business days
|Depression Drugs - Global Market Outlook (2019 -2027)|
|Published: August 1, 2020||Content info: 211 Pages||
According to Stratistics MRC, the Global Depression Drugs Market is accounted for $12.38 billion in 2019 and is expected to reach $16.68 billion by 2027 growing at a CAGR of 3.8% during the forecast period. Some of the factors such as growing healthcare expenditure and increasing insurance coverage are anticipated to fuel the market growth. However, side effects associated with these drugs along with the availability of other treatment methods such as psychotherapy is hindering the market growth.
Depression drugs are medications used to treat major depressive disorders, some anxiety disorders, chronic pain conditions, and to help manage some addictions. Common side effects of depression drugs include dry mouth, weight gain, dizziness, headaches, and sexual dysfunction.
Based on the drug class, the serotonin and norepinephrine reuptake inhibitors (SNRIs) segment is likely to have a huge demand due to SNRIs help relieve depression symptoms, essentially sadness and irritability. These neurotransmitters are known to affect mood. Serotonin is also called a "feel-good" because it is accompanied by positive feelings of wellbeing. Norepinephrine is associated with alertness and energy. SNRIs help treat depression by maintaining the levels of these two neurotransmitters in the brain. They do this by discontinuing norepinephrine and serotonin from going back into the cells that released them.
By geography, North America is estimated to have a lucrative growth owing to high patient awareness levels regarding the availability of various drugs for depression, rising healthcare expenditure and the relatively larger number of R&D exercises on drug manufacturing and marketing, etc. these factors contribute for significant revenue generation from the region.
Some of the key players profiled in the Depression Drugs Market include Abbott, Allergan, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer, AstraZeneca, Bristol-Myers Squibb, Zhejiang NHU Company Ltd, and Sebela Pharmaceuticals.
Disease Types Covered:
Drug Classes Covered:
Distribution Channels Covered:
Drug Types Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.